Ranked in 2 industries
This company is listed under more than one industry, so we show its position in each rather than picking one.
Score of 85.1/100 qualifies for PaymentCheck Certification
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 30 Jan 2026 | 15 | 83% | 15% | 2% | 50% |
| 01 Jan 2025 - 30 Jun 2025 | 31 Jul 2025 | 12 | 86% | 14% | 0% | 36% |
| 01 Jul 2024 - 31 Dec 2024 | 03 Feb 2025 | 17 | 76% | 24% | 0% | 49% |
| 01 Jan 2024 - 30 Jun 2024 | 19 Dec 2024 | 19 | 67% | 27% | 6% | 28% |
| 01 Jul 2023 - 31 Dec 2023 | 19 Dec 2024 | 16 | 78% | 22% | 0% | 37% |
| 01 Jan 2023 - 30 Jun 2023 | 19 Dec 2024 | 24 | 42% | 40% | 18% | 49% |
| 01 Jul 2022 - 31 Dec 2022 | 19 Dec 2024 | 19 | 62% | 38% | 0% | 46% |
| 01 Jan 2022 - 30 Jun 2022 | 19 Dec 2024 | 23 | 72% | 14% | 14% | 41% |
| 01 Jul 2021 - 31 Dec 2021 | 19 Dec 2024 | 23 | 72% | 14% | 14% | 41% |
| 01 Jan 2021 - 30 Jun 2021 | 19 Dec 2024 | 46 | 22% | 14% | 64% | 44% |
| 01 Jul 2020 - 31 Dec 2020 | 19 Dec 2024 | 34 | 33% | 15% | 52% | 50% |
| 01 Jan 2020 - 30 Jun 2020 | 19 Dec 2024 | 44 | 29% | 20% | 51% | 52% |
| 01 Jul 2019 - 31 Dec 2019 | 19 Dec 2024 | 21 | 57% | 24% | 19% | 59% |
| 01 Jan 2019 - 30 Jun 2019 | 19 Dec 2024 | 22 | 51% | 28% | 21% | 33% |
| 01 Jul 2018 - 31 Dec 2018 | 19 Dec 2024 | 43 | 24% | 18% | 58% | 68% |
| 01 Jan 2018 - 30 Jun 2018 | 19 Dec 2024 | 28 | 51% | 19% | 30% | 70% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Various payment terms across suppliers but 30 days is the most common.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
60
Disputes may (most commonly) arise in respect of the testing of consumables used within OXB's drug manufacture process. In this context disputes are led by the operational/scientific elements of the business in collaboration with suppliers.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Oxford Biomedica PLC is the parent company of the OXB group, which now trades under the OXB name. The group is a contract development and manufacturing organisation specialising in viral vectors for cell and gene therapy, offering process development, GMP manufacturing, analytical methods and regulatory support across lentivirus, AAV, adenovirus and other vector platforms. Operations are carried out through subsidiaries including Oxford Biomedica (UK) Ltd, Oxford Biomedica (US) Inc/LLC and Oxford Biomedica (France) SAS, with GMP facilities in the UK, US and France. The group, founded in 1995 as a University of Oxford spin-out, has manufactured viral vectors at commercial scale, including doses of the Oxford-AstraZeneca COVID-19 vaccine.
Generated from the company's website and Companies House records. Sources: oxb.com · oxb.com · oxb.com